InVitria Joins NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT)

Published on 24 June 2026

Partnership strengthens efforts to advance consistent, scalable cell therapy manufacturing

InVitria has joined the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT) as an industry member.

The partnership brings together CMaT’s leadership in cell manufacturing research with InVitria’s expertise in animal-origin-free recombinant proteins to support consistent, scalable cell therapy manufacturing.

CMaT works to transform the manufacture of cell-based therapeutics into large-scale, reproducible, and high-quality engineered processes. InVitria’s chemically defined recombinant proteins help provide reliable, xeno-free culture conditions essential for advanced cell and gene therapy workflows.

Together, this collaboration aims to accelerate innovation and improve manufacturing outcomes for cell-based therapeutics.

Read the full announcement from CMaT:

We are proud to announce CMaT’s newest industry member, InVitria, Inc.! Their expertise in animal-origin-free recombinant proteins will strengthen CMaT’s efforts to advance consistent, scalable cell therapy manufacturing. We’re excited to see how this collaboration accelerates innovation in cell therapy development.

Link to full CMaT announcement